Karyopharm Therapeutics (NASDAQ:KPTI) Receives Neutral Rating from HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a report issued on Friday, MarketBeat.com reports. The firm currently has a $3.00 price objective on the stock, down from their previous price objective of $13.00.

Several other equities analysts have also recently weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Karyopharm Therapeutics in a research note on Tuesday, June 9th. Weiss Ratings lowered shares of Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Piper Sandler restated an “overweight” rating and set a $16.00 price target (up from $8.00) on shares of Karyopharm Therapeutics in a report on Monday, April 27th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $16.00 price objective on shares of Karyopharm Therapeutics in a research report on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.50.

Karyopharm Therapeutics Stock Performance

NASDAQ KPTI opened at $1.92 on Friday. The firm’s 50 day moving average price is $8.88 and its two-hundred day moving average price is $8.19. Karyopharm Therapeutics has a twelve month low of $1.80 and a twelve month high of $10.99. The stock has a market cap of $43.51 million, a price-to-earnings ratio of -0.13 and a beta of 0.80.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Thursday, May 14th. The company reported ($1.24) EPS for the quarter, topping the consensus estimate of ($1.45) by $0.21. The business had revenue of $35.07 million during the quarter, compared to analyst estimates of $31.40 million. On average, research analysts forecast that Karyopharm Therapeutics will post -3.24 EPS for the current fiscal year.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in KPTI. Commodore Capital LP acquired a new stake in shares of Karyopharm Therapeutics during the 1st quarter valued at about $10,862,000. T. Rowe Price Investment Management Inc. increased its holdings in Karyopharm Therapeutics by 112.8% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,491,409 shares of the company’s stock worth $10,977,000 after buying an additional 790,417 shares during the last quarter. Ikarian Capital LLC increased its holdings in Karyopharm Therapeutics by 1,897.9% in the fourth quarter. Ikarian Capital LLC now owns 544,554 shares of the company’s stock worth $4,008,000 after buying an additional 517,297 shares during the last quarter. Avidity Partners Management LP raised its position in Karyopharm Therapeutics by 244.6% during the first quarter. Avidity Partners Management LP now owns 463,741 shares of the company’s stock valued at $2,583,000 after acquiring an additional 329,175 shares in the last quarter. Finally, Boothbay Fund Management LLC bought a new position in Karyopharm Therapeutics during the fourth quarter valued at approximately $1,064,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

More Karyopharm Therapeutics News

Here are the key news stories impacting Karyopharm Therapeutics this week:

• Positive Sentiment: Karyopharm plans to submit a supplemental New Drug Application in August 2026 seeking accelerated FDA approval for selinexor combined with ruxolitinib in myelofibrosis. The company will request priority review, and approval could make the treatment the first approved combination therapy in this setting. Karyopharm myelofibrosis sNDA announcement
• Positive Sentiment: Piper Sandler maintained an “overweight” rating while lowering its price target to $7.00. The target still indicates substantial potential upside if Karyopharm’s pipeline programs succeed.
• Neutral Sentiment: HC Wainwright reaffirmed its “neutral” rating but cut its price target to $3.00 from $13.00, reflecting sharply reduced expectations after the endometrial-cancer update.
• Neutral Sentiment: Robert W. Baird downgraded KPTI from “outperform” to “neutral” and set a $3.00 price target, signaling a more cautious view despite implied upside from recent trading levels.
• Neutral Sentiment: An executive vice president sold 189 shares for approximately $1,342, reducing the executive’s position by only 0.20%; the small transaction is unlikely to materially change the investment outlook. SEC insider transaction filing
• Negative Sentiment: Karyopharm’s Phase 3 XPORT-EC-042 trial failed to meet its primary progression-free-survival endpoint in endometrial cancer. Although median PFS favored selinexor by 5.3 months in the modified intent-to-treat population, the miss led the company to reduce investment in the program and refocus resources on myelofibrosis and multiple myeloma. Karyopharm XPORT-EC-042 trial results
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Karyopharm investors, adding legal overhang following the sharp decline. Pomerantz investor investigation

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.